Novo Nordisk, the manufacturer of Ozempic, has experienced a dramatic 70% drop in its stock price from its peak. Despite this decline, analysts had previously hesitated to recommend selling the stock until Deutsche Bank issued a downgrade to 'sell' on Thursday. This shift in analyst sentiment marks a significant change in the outlook for the company.
Investors should monitor Novo Nordisk's response to the downgrade and any strategic shifts it may announce. Watch for potential impacts on its product pipeline and how it addresses investor concerns in upcoming earnings calls.